Full-Time

Senior Quality Engineer

Posted on 6/23/2025

Guardant Health

Guardant Health

1,001-5,000 employees

Blood-based tests for cancer detection and management

No salary listed

Senior

San Carlos, CA, USA

Category
QA & Testing
Quality Assurance
Required Skills
Risk Management
Requirements
  • B.S. degree in Engineering, Biology, Chemistry, Molecular Biology or a related scientific discipline
  • 5+ years of quality experience in an FDA/ISO regulated environment (IVD, molecular diagnostics, or medical devices preferred)
  • Working knowledge of design and development in accordance with ISO 13485/FDA 21 CFR 820, and other applicable regulations
  • Experience with Design Controls, Risk Management, Process Validation, and Change Control
  • Experience with design control elements and design transfer
  • Hands-on experience with statistical methods, sampling plans, Statistical Process Control (SPC), and Design of Experiments (DoE)
  • Knowledge of Good manufacturing practices
  • Knowledge of Design for Manufacturing (DFM) leading to more efficient and cost-effective production
  • Ability to successfully balance and prioritize multiple ongoing projects/tasks in a fast-paced, deadline driven environment
  • Strong analytical and problem-solving skills; attention to detail is essential
  • Proficient verbal and written communication; able to communicate effectively with cross-functional stakeholders
  • Collaborative and self-motivated mindset with a drive for results and process improvement
Responsibilities
  • Develops and applies quality requirements for Guardant Health’s reagent manufacturing process and quality control activities. This includes providing guidance for Production and Process Controls, Risk Analysis, and decisions on process validation activities
  • Define and provide guidance for statistical methodologies, sampling plans, and stability testing requirements
  • Ensures required documentation is completed prior to product transfers and product launches
  • Leads all risk management and change control activities related to reagents
  • Provides guidance on process and test method validations, re-validations and participates in related change control activities
  • Support internal audits, CAPAs, nonconformance investigations, and supplier quality activities
  • Supports equipment qualification (IQ, OQ, PQ)
  • Supports review of manufacturing records and material disposition, as required
  • Support material related issues and deviations
  • Identifies opportunities for continuous improvement and collaborates with cross-functional teams to successfully address these opportunities
  • Use Statistical Process Control (SPC) to ensure product quality, to identify areas for improvement, and to reduce variability and defects
  • Generate metrics as required and report to management
  • Performs other related duties and responsibilities as assigned
  • Report and document all concerns of test quality and/or safety to the Supervisor or Safety Officer, as applicable.
Desired Qualifications
  • 5+ years of quality experience in an FDA/ISO regulated environment (IVD, molecular diagnostics, or medical devices preferred)

Guardant Health specializes in blood-based tests that provide essential information for cancer treatment and management. Their main product, Guardant360, is an FDA-approved test that helps healthcare providers make informed treatment decisions for patients with advanced cancer. The tests work by analyzing blood samples to detect cancer and monitor its progression, allowing for non-invasive diagnostics. Unlike many competitors, Guardant Health focuses on providing data-rich insights that can be used at various stages of cancer, including early detection and recurrence monitoring. The company's goal is to enhance patient outcomes and lessen the impact of cancer through innovative diagnostic solutions.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Palo Alto, California

Founded

2012

Simplify Jobs

Simplify's Take

What believers are saying

  • Guardant Health won the 2025 World Changing Ideas Award for colorectal cancer screening.
  • They partnered with Pfizer to develop cancer therapies using liquid biopsy technology.
  • Guardant Health is expanding into early-stage cancer detection and recurrence monitoring.

What critics are saying

  • Increased competition from Caris Life Sciences may impact market share and pricing power.
  • Rapid technological advancements may outpace Guardant Health's product integration capabilities.
  • Expansion into hereditary cancer testing may lead to increased regulatory scrutiny.

What makes Guardant Health unique

  • Guardant Health specializes in blood-based tests for cancer treatment and management.
  • Their flagship product, Guardant360, is FDA-approved for advanced cancer treatment decisions.
  • They focus on non-invasive diagnostics to improve patient outcomes and reduce cancer burden.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

↓ -1%

1 year growth

↑ 0%

2 year growth

↓ -1%
Guardant Health
Jun 10th, 2025
Guardant Health Wins Fast Company's 2025 World Changing Ideas Award for Shield Blood Test for Colorectal Cancer Screening

Guardant Health wins Fast Company's 2025 World Changing Ideas Award for Shield blood test for colorectal cancer screening.

NNB5
Jun 9th, 2025
Caris Life Sciences, backed by Sixth Street, targets a $5.35 billion valuation in its upcoming U.S. IPO

Competitive landscape: Caris competes with Roche's Foundation Medicine, Guardant Health, Grail, and peers like Tempus AI.

PR Newswire
Jun 4th, 2025
Leading Health Groups Launch Effort To Encourage Modernization Of Health Screening Measures

WASHINGTON, June 4, 2025 /PRNewswire/ -- A collection of public and private sector health leaders today announced a new collaboration to help ensure current health screening measures remain aligned with the rapid advancements in FDA-approved screening technologies and clinical guidelines.The Alliance for Screening Measurement Modernization (ASMM) brings together organizations from across the healthcare sector to explore a broader framework for the timely integration of evidence into currently endorsed national health screening policies."It is critically important that clinicians have what they need to keep patients healthy, including the latest diagnostics," said Lee Fleisher, M.D., M.L., ASMM chair and founder of Rubrum Advising. "The pace of technology is accelerating rapidly, but it can take more than a decade to update the quality measures that assess compliance with current health screening recommendations. This means clinicians are not incentivized to use tests that may be quicker, safer, or less invasive for patients simply because they are built on technologies that have not yet been incorporated into the latest quality measures."Over the next six months, ASMM will:Develop a replicable, transparent framework to support measure developers with timely and appropriate pathways to update currently endorsed screening quality measuresto support measure developers with timely and appropriate pathways to update currently endorsed screening quality measures Enable the evidence-based inclusion of innovative technologies that improve diagnostic speed, accuracy, and accessibilitythat improve diagnostic speed, accuracy, and accessibility Submit a consensus white paper and policy briefs to Congressional and federal agencies for considerationASMM is led by two independent but collaborative bodies: the ASMM Quality Council, whose members are guideline-setting groups and non-profit organizations, and the Industry Council, which includes organizations that are at the forefront of transforming screening technologies to support more accurate, accessible, and timely diagnoses.The Quality Council is developing the framework and will operate independently of the Industry Council, which serves as the central forum to ensure diagnostic and imaging innovators and stakeholders have a voice in the process. Together, the councils represent a range of therapeutic areas and reflect expertise in both clinical practice and quality measure development and policy.Industry Council founding members include Geneoscopy and Guardant Health and founding members of the Quality Council include ECRI, Friends of Cancer Research, Milken Institute's FasterCures, URAC, and others.SOURCE The Alliance for Screening Measurement Modernization

Insider Monkey
May 31st, 2025
Guardant Health, Inc. (GH)'s ctDNA Test Predicts Colon Cancer Recurrence Risk in Stage III Patients

Guardant Health, Inc. (NASDAQ:GH) and research collaborators have unveiled results from the largest study to date on circulating tumor DNA (ctDNA) testing in stage III colon cancer, presented at the 2025 ASCO Annual Meeting.

Guardant Health
May 27th, 2025
Guardant Health Introduces Nearly a Dozen Groundbreaking Smart Liquid Biopsy Applications for Guardant360 Liquid Test

Guardant Health introduces nearly a dozen groundbreaking Smart Liquid Biopsy applications for Guardant360 Liquid test.

INACTIVE